Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/57560
Title: Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
Authors: 
Keywords: 
Mesh: 
Issue Date: 7-May-2019
Citation: BMC Gastroenterol.2019;(19)1:69
Abstract: Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastrointestinal and nervous system components. The study aim was to assess the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK). An observational, one year retrospective-prospective (6 months each) study of patients diagnosed in the last five years with IBS-C (Rome III criteria) and moderate to severe disease at inclusion (IBS Symptom Severity Scale score ≥ 175). The primary objective was to assess the direct cost to European healthcare systems. Five hundred twenty-five patients were included, 60% (range: 43.1-78.8%) suffered from severe IBS-C. During follow-up 11.1-24.0% of patients had a hospitalisation/emergency room (ER) visit, median stay range: 1.5-12.0 days and 41.1-90.4% took prescription drugs for IBS-C. 21.4-50.8% of employed patients took sick leave (mean: 11.6-64.1 days). The mean annual direct cost to the healthcare systems was €937.1- €2108.0. The total direct cost (combined costs to healthcare systems and patient) for IBS-C was €1421.7-€2487.1. IBS-C is not a life-threatening condition; however, it has large impact on healthcare systems and society. Direct and indirect costs for moderate to severe IBS-C were high with the largest direct cost driver being hospitalisations/ER visits.
PMID: 31064345
URI: https://hdl.handle.net/20.500.12530/57560
Rights: openAccess
Appears in Collections:Hospitales > H. U. Tajo > Artículos

Files in This Item:
File SizeFormat 
PMC6505116.pdf965.14 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons